AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01407263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse versus vertical closure
Description: Transverse versus vertical closure of the port site incision
Study NCT01407263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic prophylaxis
Description: One vs. three days of antibiotic prophylaxis at catheter removal
Study NCT01407263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemostatic Agent
Description: For the patients randomized to routine indwelling HA agent use, the operating surgeon may choose to use either Surgicel™, Surgicel SNoW™, Arista™, FloSeal or surgeon's choice HA directed at the prostatic fossa, ligated dorsal vein complex, or neurovascular bundles. Because there is no standard HA or method of application, the surgeon will apply the HA according to the surgeon's experience and document both the HA used, and the location applied in the operative report. For patients randomized to no routine indwelling HA use, surgeons will only apply a HA if they are unable to achieve hemostasis using traditional means or feel it would be unsafe to complete the operation without using a HA for additional hemostasis. Providers in either arm may use HA as needed provided the intention is not to leave the HA indwelling.
Study NCT01930916 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: INR capillary measurement with INRatio 2 device
Description: INR capillary measurement with INRatio 2 device
Study NCT01930916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: antiphospholipid antibodies and lupus anticoagulant
Description: Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
Study NCT02003755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle continuous passive motion machine.
Description: A rehabilitation program of machine driven passive stretch.
Study NCT04084002 — intervention group
Intervention type: OTHER
Intervention: physical activity measurement
Description: Physical activity will be measured via accelerometer and self reported questionnaire (Physical activity scale for elderly)
Study NCT02954328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
Study NCT01263717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tesamorelin
Description: Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
Study NCT01263717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
Study NCT02006199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness meditation
Description: 8 weeks of mindfulness meditation specified for OCD patient
Study NCT01543802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
Study NCT00551174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
Study NCT00551174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibandronate [Bonviva/Boniva]
Description: 2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
Study NCT01534416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
Study NCT01534416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
Study NCT00205660 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stayers
Description: Participants remain on their current antipsychotic.
Study NCT00205660 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Switchers
Description: Subjects are randomized to switch to aripiprazole from their current antipsychotic.
Study NCT01768559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection 30 to 60 minutes before breakfast or dinner.
Study NCT01768559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine QD
Description: Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before breakfast or dinner. The initial dose was 3-5 units and then individually titrated to obtain the SMPG value >5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before lunch (if administered at breakfast) or at bedtime (if administered at dinner).
Study NCT01768559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine TID
Description: Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before each meal. The initial dose was 3-5 units for each meal and then individually titrated to obtain the SMPG value >5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before the next meal or at bedtime (for injection at dinner).
Study NCT01768559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine (Mandatory background drug)
Description: Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).
Study NCT01768559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine (Mandatory background drug)
Description: Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).
Study NCT01768559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin (Background drug)
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.
Study NCT01768559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (Background drug)
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.
Study NCT03099603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HTD1801
Description: A small molecular compound for the treatment of primary sclerosing cholangitis
Study NCT02709837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional
Study NCT03486405 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group runners will receive the same graduated return to run intervals and 4-week home exercise program. However, they will receive no video education during the initial 10 weeks.
Study NCT03486405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Runners randomized to the intervention group will receive additional video tele-health instruction on how to transition to a non-rearfoot strike (NRFS) running pattern. Runners in the intervention group will have additional tele-health follow-ups at weeks 1, 2, 4,6, 8, and 10 using a tele-conferencing program and the Hudl Technique application. At each tele-health video follow-up participants will be emailed a questionnaire assessing their progress and function. At month 6 a final data collection session to include video analysis will be performed.
Study NCT00622102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery arm (Lottery and Med-eMonitor)
Description: Lottery and Med-eMonitor
Study NCT00622102 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-Lottery (Med-eMonitor only)
Description: Med-eMonitor only
Study NCT04716374 — intervention group
Intervention type: OTHER
Intervention: Tumor molecular profiling
Description: Tumor tissue processing and all NGS genotyping were performed at the Laboratory of Molecular Oncology (Hellenic Foundation for Cancer Research / AUTH). Paraffin H\&E sections from the retrieved tissue blocks were centrally reviewed for tumor histology and tissue adequacy for DNA extraction and were marked for macrodissection along with tumor DNA content \[(former tumor cell content (TCC%)\] assessment. DNA was extracted from macrodissected tissue fragments with the QIAamp® DNA mini kit (Qiagen, Hilden, Germany), measured in a Qubit fluorometer (Thermo Fisher Scientific, Paisley, UK), and genotyped with NGS in an Ion Torrent Proton sequencer (Thermo Fisher Scientific) by using a previously published custom panel (Kotoula, Lakis et al. 2019). Following stringent variant quality filtering (Kotoula, Chatzopoulos et al. 2021), 500 tumors
Study NCT03163316 — intervention group
Intervention type: OTHER
Intervention: Unenhanced magnetic resonance imaging.
Description: The axillary lymph nodes will be evaluated on axial Time 1-weighted images obtained without fat saturation. We will measure the largest dimension and cortical thickness of each lymph node and ratio of the two measurements will be calculated.~The lymph nodes seen in Time 1-weighted images will be subsequently identified on the diffusion-weighted images to calculate the apparent diffusion coefficient value of each lymph node.~Axillary lymph nodes scanned by magnetic resonance imaging will be compared by results of histopathological examination.
Study NCT02008136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins
Description: intramuscular injections
Study NCT04530929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SANPROBI BARRIER
Description: Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
Study NCT04530929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Competitors used placebo for three months at a dose of 2x2 capsules daily.
Study NCT01514110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Pharmacology of RAD001 as a combination partner for conventional agents.
Study NCT00672607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extracts of Vitex agnus castus tablets
Description: orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
Study NCT00672607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02638974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Skin Camouflage
Description: Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
Study NCT02186977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAX-ID
Description: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
Study NCT02186977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
Description: 1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
Study NCT02186977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)
Description: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
Study NCT05680428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early feeding
Description: oral feeding within 12hours after stoma reversal
Study NCT05680428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional feeding
Description: oral feeding after 48hours of NBM after stoma reversal
Study NCT02454010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FF21101
Description: (90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)
Study NCT02204345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin by intravenous infusion q3w for 4-6 cycles and thereafter as per investigator's discretion.
Study NCT02204345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel by intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
Study NCT02204345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5479599
Description: RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
Study NCT04156893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red cell units that are genotype matched at the RHD and RHCE loci
Description: Patients will be provided with red cell units that are C, E, and K antigen matched (standard of care for patients with SCD) and genotype matched at the RHD and RHCE loci.
Study NCT00186485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagStim
Description: The MagStim delivers low frequency 1Hz stimulation to the right frontal area of the brain
Study NCT03305692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optimization of CRT Device
Description: Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.
Study NCT03895203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab will be administered according to the labeling recommendations.
Study NCT03698539 — intervention group
Intervention type: BEHAVIORAL
Intervention: hand gestures
Description: We observe the use of spontaneous hand gestures in all the groups.
Study NCT03774888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft at time of bone graft
Description: following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
Study NCT03774888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acellular Demal Matrix at time of bone graft
Description: following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
Study NCT03774888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No soft tissue grafting at time of bone graft
Description: Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
Study NCT00573872 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Phase I: 20-25 Gy in 5 fractions~Phase II: 9-24 GY in 1 fraction
Study NCT02768688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain connectivity and physiology
Description: MRI to measure glymphactic flow during simulated natural sleep and again on return to wakefulness.
Study NCT02768688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Administering of 0.5-1.0 mcg/kg/hr of dexmedetomidine to ensure subject's loss of consciousness.
Study NCT03243305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMPHORA
Description: non-hormonal contraceptive vaginal gel
Study NCT02250456 — intervention group
Intervention type: PROCEDURE
Intervention: Echo doppler
Description: vascular ultrasound explorations
Study NCT02216279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PulmoBind
Description: PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
Study NCT02216279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PulmoBind
Description: PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
Study NCT05030532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVERYbody Project
Description: Brief behavioral group intervention (4 hours across two meetings)
Study NCT05030532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video + Expressive Writing
Description: Brief video-based group intervention (4 hours across two meetings)
Study NCT03234803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: poly-amide
Description: new denture base material
Study NCT03234803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: poly-methyl methacrylate
Description: gold standard for denture base materials
Study NCT01211145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study NCT01211145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: 0.5 mg nasal spray
Study NCT01211145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: 2.5 mg nasal spray
Study NCT01211145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: 5.0 mg nasal spray
Study NCT04004260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavior Therapy
Description: The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
Study NCT04004260 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet-based Cognitive Behavior Therapy
Description: The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
Study NCT01497067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF CACHET Phakic Lens (L-series)
Description: Intraocular lens for the treatment of moderate to high myopia
Study NCT00673257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: pharmacological studies
Study NCT00673257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dual x-ray absorptimetry
Study NCT01472445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT03895203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points.
Study NCT03895203 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points.
Study NCT02616445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UE2343
Description: * UE2343~* 10mg, 20, 35mg~* twice daily for 9 days
Study NCT02616445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * 10mg, 20, 35mg~* twice daily for 9 days
Study NCT02616445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Cross-over study~* single dose administered twice (on day 1 and day 8)~* study duration 17 days
Study NCT02616445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UE2343
Description: * Cross-over study~* UE2343~* single dose administered twice (on day 1 and day 8)~* study duration 17 days
Study NCT02616445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UE2343
Description: * UE2343~* twice daily for 3 days~* single dose on day 4
Study NCT03955159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Description: The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
Study NCT03955159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic supplementation
Description: The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.